Medtronic Stock Price, News & Analysis

Medtronic (NYSE: MDT) announced FDA clearance of the Hugo™ robotic-assisted surgery (RAS) system for use in minimally invasive urologic procedures including prostatectomy, nephrectomy, and cystectomy.

The release notes the Expand URO IDE study—described as the largest US multi-port robotic urology trial—met primary safety and effectiveness endpoints, and estimates those urologic procedures total about 230,000 surgeries per year in the U.S. Medtronic plans a purposeful U.S. launch with broader specialty indications expected later.

Medtronic (NYSE: MDT) announced the U.S. commercial launch of the MiniMed 780G system integrated with the Instinct sensor, made by Abbott, on Dec 2, 2025. The system received U.S. FDA clearance earlier in 2025 to enable integration with Instinct and is now shipping nationwide.

The Instinct sensor offers up to 15 days wear and is described as the world's smallest and thinnest integrated CGM; when paired with MiniMed 780G it provides real-time glucose readings and automates insulin adjustments every 5 minutes.

Medtronic (NYSE: MDT) reported Q2 FY26 revenue of $8.96B, up 6.6% reported and 5.5% organic, and GAAP diluted EPS of $1.07 (+8%). Non-GAAP diluted EPS was $1.36 (+8%).

Highlights include Cardiac Ablation Solutions +71% (PFA portfolio), Cardiovascular revenue $3.436B (+10.8%), Diabetes revenue $757M (+10.3%), and several regulatory/coverage wins (CMS NCD for Symplicity, FDA approvals for Altaviva and MiniMed 780G updates).

The company raised FY26 guidance to ~5.5% organic revenue growth and $5.62–$5.66 adjusted EPS; tariffs could reduce results by about $185M.

Medtronic (NYSE: MDT) will report second-quarter fiscal 2026 results on Tuesday, November 18, 2025, covering the quarter ended October 24, 2025. A summary news release will be issued at approximately 5:45 a.m. CST at https://news.medtronic.com and a video webcast discussing results will begin at 7:00 a.m. CST at https://investorrelations.medtronic.com.

A replay and transcript of prepared remarks will be available within 24 hours via the Events link on the investor site. Medtronic also plans to report FY2026 Q3 results on February 17, 2026 and Q4 results on May 20, 2026, with confirmations to follow. Medtronic is a global healthcare technology company headquartered in Galway with more than 95,000 employees and technologies treating 70 health conditions.

Medtronic (NYSE: MDT) announced that the U.S. Centers for Medicare & Medicaid Services finalized a National Coverage Determination (NCD) for renal denervation on Oct. 28, 2025, extending Medicare coverage to qualifying patients for the Symplicity Spyral™ RDN system (the Symplicity blood pressure procedure) to treat uncontrolled hypertension.

The Symplicity Spyral system was approved by the FDA in November 2023, is available in nearly 80 countries, and is positioned by the company as a commercial growth driver as adoption expands across major U.S. hypertension centers and integrated delivery networks.

Medtronic (NYSE: MDT) reported 3‑year SPYRAL HTN‑ON MED results showing sustained blood pressure reductions after Symplicity Spyral renal denervation (RDN) versus sham in patients on antihypertensive medications.

Key 3‑year results: 24‑hr ABPM −14.0 mmHg (RDN) vs −9.3 mmHg (sham; treatment difference −4.7 mmHg; p=0.0028) and office SBP −18.5 mmHg vs −11.7 mmHg (treatment difference −7.4 mmHg; p=0.0002). No renal artery stenosis >70% was observed through three years.

The data were presented at TCT 2025; the Symplicity system is marketed in nearly 80 countries.

Medtronic (NYSE: MDT) announced that BrainSense Adaptive Deep Brain Stimulation (aDBS) was named a 2025 TIME Best Inventions. The sensing-enabled Percept neurostimulator with BrainSense personalizes Parkinson's therapy by adjusting stimulation in real time.

Medtronic said it received both CE Mark and U.S. FDA approval for BrainSense aDBS earlier in 2025, published pivotal results in JAMA Neurology (ADAPT-PD) showing clinical effectiveness, and reported that more than 1,000 patients worldwide have received adaptive therapy.

Medtronic (NYSE: MDT) launched the Embrace Gynecology U.S. IDE clinical study to evaluate the Hugo™ robotic-assisted surgery system for hysterectomy procedures, with enrollment underway and up to 70 patients planned across up to 5 U.S. hospitals. The first total hysterectomy procedures were completed at AHN West Penn Hospital in Pittsburgh on Oct. 8, 2025. Embrace Gynecology is prospective and includes radical, modified radical, and total hysterectomies, inclusive of malignancy cases. This becomes the third U.S. IDE for Hugo RAS after Expand URO and Enable Hernia Repair, both of which met primary safety and effectiveness endpoints. The company notes Hugo RAS is in clinical use in 30+ countries and is CE marked in the EU; in the U.S. the device remains investigational.

Medtronic plc (NYSE: MDT) has announced the successful closing of a public offering through its subsidiary Medtronic, Inc., consisting of €1.5 billion in senior notes. The offering includes €750 million of 2.950% senior notes due 2030 and €750 million of 4.200% senior notes due 2045.

The company raised net proceeds of approximately €1.49 billion after deducting underwriting discounts and expenses. These funds will be used to repay Medtronic Luxco's existing 0.000% Senior Notes and 2.625% Senior Notes, both due in 2025. Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC served as joint book-running managers for the offering.